Corcept Therapeutics Incorporated will announce its second quarter financial results and provide a corporate update on July 29, 2026. The company will also host a conference call on the same day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the results and business developments.

Participants must register in advance of the conference call to receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available for those who wish to follow the proceedings without participating.

A replay of the call will be accessible on the Investors / Events tab of Corcept.com after the event. The company has not disclosed specific financial metrics or guidance ahead of the announcement.

Corcept Therapeutics has focused on cortisol modulation for over 25 years, discovering more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. The company is conducting advanced clinical trials in patients with Cushing’s syndrome, solid tumors, ALS, and liver disease.

In 2012, Corcept introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with endogenous Cushing’s syndrome. In 2026, the company introduced Lifyorli™, approved in combination with nab-paclitaxel, as the first FDA-approved selective glucocorticoid receptor antagonist for adults with platinum-resistant ovarian cancer. Corcept is headquartered in Redwood City, California.

Kuehn Law, PLLC is investigating whether certain officers and directors of Corcept Therapeutics Incorporated breached their fiduciary duties to shareholders regarding the disclosure of material information. The law firm's inquiry centers on allegations that the company failed to communicate adverse facts concerning the potential FDA approval of relacorilant, a medication developed for multiple indications including the treatment of hypercortisolism, or Cushing's syndrome.

According to a federal securities lawsuit, while Corcept Therapeutics Incorporated touted the expected success of FDA approval, it did not disclose that the FDA had expressed concerns about the adequacy of the company's clinical development program. The lawsuit alleges that these concerns created a material risk that the New Drug Application for relacorilant could be rejected.

The investigation focuses on the period leading up to the potential rejection of the application. Shareholders are advised that the company's public statements regarding the drug's prospects may have been misleading given the regulatory feedback it had received.

Kuehn Law is encouraging investors who currently own shares of Corcept Therapeutics Incorporated and purchased them prior to October 31, 2024, to come forward. The firm has stated that it pays all case costs and does not charge its investor clients for representation.

Shareholders interested in learning more about the investigation or their rights are urged to contact Kuehn Law immediately, as there may be limited time to enforce legal rights.